

## Anti-EGFR CAR T Cells

<b>Drug Name</b>	***0005
<b>Description</b>	A cancer immunotherapy consisting of human autologous T cells expressing CXCR5 and a chimeric antigen receptor (CAR) targeting human epidermal growth factor receptor (EGFR) is in a phase I clinical trial for the treatment of patients with non-small cell lung cancer (NSCLC).
<b>Target</b>	Epidermal Growth Factor Receptor (EGFR)
<b>Drug Modality</b>	CAR T cells
<b>Indication</b>	Non-Small Cell Lung Cancer (NSCLC)
<b>Product Category</b>	Cancer Immunotherapy
<b>Mechanism of Action</b>	Targeting EGFR-expressing tumor cells to induce selective cytotoxicity and cytolysis
<b>Status</b>	Phase I
<b>Patent</b>	Granted

### More Detail Available Upon Request

We look forward to hearing from you.